FDA Approves Supplemental Application for QTERN (Dapagliflozin/Saxagliptin)
The FDA has approved a supplemental application for QTERN, a combination of dapagliflozin and saxagliptin.
Asset / Drug
Drug and asset intelligence for QTERN with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
SGLT2 Inhibitor
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.